PDCD1 and mature T-cell and NK-cell non-Hodgkin lymphoma: The use of PD-1/PD-L1 inhibitors in PTCL is encouraging based on current knowledge, especially for ENKTL, with patients with high PD-L1 expression benefiting the most.